Inspire Investing LLC Buys 27,701 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Inspire Investing LLC lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 175.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,524 shares of the biopharmaceutical company’s stock after acquiring an additional 27,701 shares during the period. Inspire Investing LLC’s holdings in Royalty Pharma were worth $1,322,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC acquired a new position in Royalty Pharma during the first quarter worth approximately $46,000. Allworth Financial LP increased its position in Royalty Pharma by 76.7% during the fourth quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 731 shares during the last quarter. GAMMA Investing LLC increased its position in Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 802 shares during the last quarter. Finally, Lindbrook Capital LLC increased its position in Royalty Pharma by 485.2% during the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 1,999 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Up 2.6 %

RPRX traded up $0.70 on Tuesday, hitting $27.35. The company had a trading volume of 740,863 shares, compared to its average volume of 2,689,798. The company has a debt-to-equity ratio of 0.62, a current ratio of 12.52 and a quick ratio of 12.52. Royalty Pharma plc has a 52-week low of $25.20 and a 52-week high of $31.66. The stock has a fifty day simple moving average of $26.91 and a 200-day simple moving average of $28.37. The firm has a market capitalization of $16.34 billion, a P/E ratio of 19.89, a P/E/G ratio of 3.49 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. The firm had revenue of $568.00 million during the quarter, compared to analyst estimates of $671.45 million. During the same period last year, the business earned $1.60 earnings per share. As a group, equities analysts expect that Royalty Pharma plc will post 4.04 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 17th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 3.07%. The ex-dividend date was Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is currently 62.69%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a report on Monday, June 3rd. Bank of America reduced their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Finally, StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.80.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.